Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort.
Morris KA, Golding JF, Blesing C, Evans DG, Ferner RE, Foweraker K, Halliday D, Jena R, McBain C, McCabe MG, Swampillai A, Warner N, Wilson S, Parry A, Afridi SK; UK NF2 research group. Morris KA, et al. Among authors: mcbain c. J Neurooncol. 2017 Jan;131(1):117-124. doi: 10.1007/s11060-016-2276-9. Epub 2016 Oct 28. J Neurooncol. 2017. PMID: 27796735
Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.
Lassen U, Chinot OL, McBain C, Mau-Sørensen M, Larsen VA, Barrie M, Roth P, Krieter O, Wang K, Habben K, Tessier J, Lahr A, Weller M. Lassen U, et al. Among authors: mcbain c. Neuro Oncol. 2015 Jul;17(7):1007-15. doi: 10.1093/neuonc/nov019. Epub 2015 Feb 9. Neuro Oncol. 2015. PMID: 25665807 Free PMC article. Clinical Trial.
Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients.
Hexter A, Jones A, Joe H, Heap L, Smith MJ, Wallace AJ, Halliday D, Parry A, Taylor A, Raymond L, Shaw A, Afridi S, Obholzer R, Axon P, King AT; English Specialist NF2 Research Group; Friedman JM, Evans DG. Hexter A, et al. J Med Genet. 2015 Oct;52(10):699-705. doi: 10.1136/jmedgenet-2015-103290. Epub 2015 Aug 14. J Med Genet. 2015. PMID: 26275417
Brain tumor research in the United Kingdom: current perspective and future challenges. A strategy document from the NCRI Brain Tumor CSG.
Kurian KM, Jenkinson MD, Brennan PM, Grant R, Jefferies S, Rooney AG, Bulbeck H, Erridge SC, Mills S, McBain C, McCabe MG, Price SJ, Marino S, Moyes E, Qian W, Waldman A, Vaqas B, Keatley D, Burchill P, Watts C. Kurian KM, et al. Among authors: mcbain c. Neurooncol Pract. 2018 Mar;5(1):10-17. doi: 10.1093/nop/npx022. Epub 2017 Aug 30. Neurooncol Pract. 2018. PMID: 31385960 Free PMC article. Review.
Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial.
Hanna C, Kurian KM, Williams K, Watts C, Jackson A, Carruthers R, Strathdee K, Cruickshank G, Dunn L, Erridge S, Godfrey L, Jefferies S, McBain C, Sleigh R, McCormick A, Pittman M, Halford S, Chalmers AJ. Hanna C, et al. Among authors: mcbain c. Neuro Oncol. 2020 Dec 18;22(12):1840-1850. doi: 10.1093/neuonc/noaa104. Neuro Oncol. 2020. PMID: 32347934 Free PMC article. Clinical Trial.
Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution.
Forde C, King AT, Rutherford SA, Hammerbeck-Ward C, Lloyd SK, Freeman SR, Pathmanaban ON, Stapleton E, Thomas OM, Laitt RD, Stivaros S, Kilday JP, Vassallo G, McBain C, Kerrigan S, Smith MJ, McCabe MG, Harkness EF, Evans DG. Forde C, et al. Among authors: mcbain c. Neuro Oncol. 2021 Jul 1;23(7):1113-1124. doi: 10.1093/neuonc/noaa284. Neuro Oncol. 2021. PMID: 33336705 Free PMC article.
CovidNeuroOnc: A UK multicenter, prospective cohort study of the impact of the COVID-19 pandemic on the neuro-oncology service.
Fountain DM, Piper RJ, Poon MTC, Solomou G, Brennan PM, Chowdhury YA, Colombo F, Elmoslemany T, Ewbank FG, Grundy PL, Hasan MT, Hilling M, Hutchinson PJ, Karabatsou K, Kolias AG, McSorley NJ, Millward CP, Phang I, Plaha P, Price SJ, Rominiyi O, Sage W, Shumon S, Silva IL, Smith SJ, Surash S, Thomson S, Lau JY, Watts C, Jenkinson MD; British Neurosurgical Trainee Research Collaborative (BNTRC). Fountain DM, et al. Neurooncol Adv. 2021 Jan 28;3(1):vdab014. doi: 10.1093/noajnl/vdab014. eCollection 2021 Jan-Dec. Neurooncol Adv. 2021. PMID: 34056602 Free PMC article.
Radiation treatment of benign tumors in NF2-related-schwannomatosis: A national study of 266 irradiated patients showing a significant increase in malignancy/malignant progression.
Evans DG, Halliday D, Obholzer R, Afridi S, Forde C, Rutherford SA, Hammerbeck-Ward C, Lloyd SK, Freeman SM, Pathmanaban ON, Thomas OM, Laitt RD, Stivaros S, Kilday JP, Vassallo G, McBain C, Lavin T, Paterson C, Whitfield G, McCabe MG, Axon PR, Halliday J, Mackeith S, Parry A; English Specialist NF2 Research Group; Harkness EF, Buttimore J, King AT. Evans DG, et al. Among authors: mcbain c. Neurooncol Adv. 2023 Mar 11;5(1):vdad025. doi: 10.1093/noajnl/vdad025. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37051330 Free PMC article.
225 results